Last reviewed · How we verify
Part B: Expansion Cohort of Cantrixil — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Part B: Expansion Cohort of Cantrixil (Part B: Expansion Cohort of Cantrixil) — Kazia Therapeutics Limited.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Part B: Expansion Cohort of Cantrixil TARGET | Part B: Expansion Cohort of Cantrixil | Kazia Therapeutics Limited | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Part B: Expansion Cohort of Cantrixil CI watch — RSS
- Part B: Expansion Cohort of Cantrixil CI watch — Atom
- Part B: Expansion Cohort of Cantrixil CI watch — JSON
- Part B: Expansion Cohort of Cantrixil alone — RSS
Cite this brief
Drug Landscape (2026). Part B: Expansion Cohort of Cantrixil — Competitive Intelligence Brief. https://druglandscape.com/ci/part-b-expansion-cohort-of-cantrixil. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab